France· FR:63275561
BEKEMV 300 mg, solution à diluer pour perfusion
A medicinal product containing éculizumab, registered in France by AMGEN TECHNOLOGY (IRELAND).
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- ÉCULIZUMAB
- Manufacturer
- AMGEN TECHNOLOGY (IRELAND)
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- No
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
- cip1334009550956511 flacon en verre de 30 mL
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Éculizumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NetherlandsBEKEMV 300 mg concentraat voor oplossing voor infusieAmgen Europe B.V.
- United StatesBKEMVAmgen Inc
- IrelandBEKEMV 300 mg Concentrate for solution for infusionAmgen Technology (Ireland) Unlimited Company
- NorwayBekemvAmgen Technology Ireland
- PolandBekemvAmgen Technology (Ireland) UC
- SwedenBEKEMV 300 mg Koncentrat till infusionsvätska, lösningAmgen Europe B.V.
- CzechiaBEKEMVAmgen Europe B.V., Breda
- SpainBEKEMV 300 MG CONCENTRADO PARA SOLUCION PARA PERFUSIONAmgen Technology (Ireland) Unlimited Company
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Bekemv, Soliris
- Liechtenstein · Soliris
- Norway · Bekemv, Soliris
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f0d05e11-59df-46e9-ae0a-c2bf3db40c99 GET /v1/drugs/f0d05e11-59df-46e9-ae0a-c2bf3db40c99?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "63275561",
"date_amm": "2023-04-19",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/23/1727",
"substance": "ÉCULIZUMAB",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "solution à diluer pour perfusion",
"voies_administration": "intraveineuse",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Oui"
}See everything about éculizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.